News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pfizer Inc. (PFE) Execs Claim AstraZeneca PLC (AZN) Takeover Could Improve R&D


5/7/2014 7:02:22 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

I spoke to Pfizer's PFE -0.38% executive team yesterday after their earnings call. A few things they said seem worth passing on in light of the company’s ongoing effort to buy AstraZeneca AZN -0.42% and its plans for its internal R&D.

Do the three businesses – (1) innovative drugs, (2) vaccines, oncology, and consumer health, and (3) established products – have scale to stand on their own? Pfizer CEO Ian Read corrected me that there would be two businesses, a combination of the first two and a global established products business. “We haven’t taken the decision. It’s very premature as to whether they should be separated,” Read said.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters
Read at Forbes


comments powered by Disqus
Reuters
Forbes
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES